/u/montaukwhaler's posts

Year:

Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients

2 upvotes • r/nsclc

Mark as read: Add to a list

WNT5B promotes the malignant phenotype of non-small cell lung cancer via the FZD3–DVL3–RAC1–PCP–JNK pathway

2 upvotes • r/nsclc

Mark as read: Add to a list

Repurposing Antiviral Drugs as Potential Anti-EGFR Agents in NSCLC: A Structure-Based Screening and Molecular Dynamics Analysis

2 upvotes • r/nsclc

Mark as read: Add to a list

CT-based different regions of interest radiomics analysis for acute radiation pneumonitis in patients with locally advanced NSCLC after chemoradiotherapy

2 upvotes • r/nsclc

Mark as read: Add to a list

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

2 upvotes • r/nsclc

Mark as read: Add to a list

Analysis of surgical complexity and short-term prognostic indicators in NSCLC patients: neoadjuvant targeted therapy versus neoadjuvant chemoimmunotherapy

2 upvotes • r/nsclc

Mark as read: Add to a list

Role of SFRP5 in Non-Small Cell Lung Cancer and Its Correlation with SUV of 18F-FDG PET-CT

2 upvotes • r/nsclc

Mark as read: Add to a list

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

2 upvotes • r/nsclc

Mark as read: Add to a list

Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study

1 upvotes • r/nsclc

Mark as read: Add to a list

Epidermal growth factor receptor and programmed cell death-1 expression levels in peripheral T cell subsets of patients with non-small cell lung cancer

1 upvotes • r/nsclc

Mark as read: Add to a list

Title	Upvotes	Subreddit	Mark as read	Favorited	Rating	Add to a list
Homologous recombination deficiency status predicts response to immunotherapy-based treatment in non-small cell lung cancer patients	2	nsclc
WNT5B promotes the malignant phenotype of non-small cell lung cancer via the FZD3–DVL3–RAC1–PCP–JNK pathway	2	nsclc
Repurposing Antiviral Drugs as Potential Anti-EGFR Agents in NSCLC: A Structure-Based Screening and Molecular Dynamics Analysis	2	nsclc
CT-based different regions of interest radiomics analysis for acute radiation pneumonitis in patients with locally advanced NSCLC after chemoradiotherapy	2	nsclc
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC	2	nsclc
Analysis of surgical complexity and short-term prognostic indicators in NSCLC patients: neoadjuvant targeted therapy versus neoadjuvant chemoimmunotherapy	2	nsclc
Role of SFRP5 in Non-Small Cell Lung Cancer and Its Correlation with SUV of 18F-FDG PET-CT	2	nsclc
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial	2	nsclc
Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study	1	nsclc
Epidermal growth factor receptor and programmed cell death-1 expression levels in peripheral T cell subsets of patients with non-small cell lung cancer	1	nsclc